NCT01808222View on ClinicalTrials.gov

FACBC for Recurrent Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

September 13, 2017

Study Completion Date

September 13, 2017

Conditions
Recurrent Prostate Cancer
Interventions
DRUG

FACBC

Participants will receive a bolus of anti-\[18F\]FACBC injected IV over 1-2 minutes. The dosage will be approximately 10.0 millicuries (mCi) (3.70 x 108 becquerel (Bq)).

Trial Locations (1)

30322

Emory University Hospital, Atlanta

All Listed Sponsors
lead

David M. Schuster, MD

OTHER

NCT01808222 - FACBC for Recurrent Prostate Cancer | Biotech Hunter | Biotech Hunter